Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors (MYTHIC)
Estudio de fase 1 de seguridad, farmacocinética, farmacodinámica y actividad clínica preliminar de RP-6306 solo o en combinación con RP-3500 en pacientes con tumores sólidos avanzados
The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Phase 1/1b, multi-center, open-label, dose-escalation study to:
- Evaluate the safety profile and MTD of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib when administered orally to establish the recommended Phase 2 dose and schedule
- Characterize the PK and pharmacodynamics of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib
- Assess preliminary anti-tumor activity associated with lunresertib alone and in combination with RP-3500 or in combination with zedoresertib
This study was previously posted by Repare Therapeutics. In September 2025, sponsorship of the trial was transferred to Debiopharm International S.A
Expanded Access Status: There is no expanded access program available for the investigational products in this study at this time.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Debiopharm International S.A
- Número de teléfono: +41 21 321 01 11
- Correo electrónico: clinicaltrials@debiopharm.com
Ubicaciones de estudio
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 1X8
- Terminado
- #2002, The Hospital for Sick Children
-
Toronto, Ontario, Canadá, M5G 2C1
- Reclutamiento
- #2001, Princess Margaret Cancer Centre
-
-
Quebec
-
Montreal, Quebec, Canadá, H4A 3J1
- Terminado
- #2003, The Research Institute of the McGill University Health Centre
-
-
-
-
-
Copenhagen, Dinamarca
- Reclutamiento
- #4001, Rigshospitalet - Blegdamsvej
-
-
-
-
-
Madrid, España, 28027
- Aún no reclutando
- Clinica Universidad de Navarra
-
Madrid, España, 28050
- Reclutamiento
- Hospital Universitario HM Sanchinarro
-
Madrid, España, 28040
- Reclutamiento
- START Madrid. Hospital Fundación Jimenez Diaz
-
Navarra, España, 31008
- Aún no reclutando
- Clinica Universidad de Navarra
-
-
-
-
California
-
Los Angeles, California, Estados Unidos, 90095
- Terminado
- # 1019, UCLA, Westwood Cancer Center
-
San Francisco, California, Estados Unidos, 94158
- Reclutamiento
- #1025, University of California San Francisco
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06520
- Reclutamiento
- #1012, Yale
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32224
- Reclutamiento
- #1017, Mayo Clinic
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Reclutamiento
- #1002, Dana Farber Cancer Institute
-
-
Michigan
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Reclutamiento
- #1023, START Midwest
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55902
- Reclutamiento
- #1016, Mayo Clinic
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63130
- Reclutamiento
- #1011, Washington University
-
-
New York
-
New Hyde Park, New York, Estados Unidos, 11042
- Reclutamiento
- #1032, Northwell Health Cancer Institute
-
New York, New York, Estados Unidos, 10065
- Reclutamiento
- #1004, Memorial Sloan Kettering Cancer Institute
-
New York, New York, Estados Unidos, 10032
- Terminado
- #1008, Columbia University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Terminado
- #1010, University of Pennsylvania
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02903
- Reclutamiento
- #1007, Rhode Island Hospital
-
Providence, Rhode Island, Estados Unidos, 02903
- Reclutamiento
- #1030, Women & Infants Hospital of Rhode Island
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- #1001, The University of Texas M.D. Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84112
- Reclutamiento
- #1013, The University of Utah
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22903
- Reclutamiento
- #1027, University of Virginia
-
-
-
-
-
London, Reino Unido, W1G 6AD
- Reclutamiento
- #3003, Sarah Cannon Research Institute
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Male or female and ≥12 years-of-age at the time of informed consent.
- Lansky performance status ≥50% for patients ≤16 years of age, or ECOG score of 0, 1, (or 2 for module 1) for patients >16 years of age.
- Locally advanced or metastatic resistant or refractory solid tumors.
- Patients <18 years of age must weigh at least 40 kg.
- Submission of available tumor tissue at screening or willingness to have a biopsy performed if safe and feasible
- Next generation sequencing (NGS) report obtained in a CLIA-certified or equivalent laboratory demonstrating eligible tumor biomarker.
- CCNE1 amplification (non-equivocal) as determined by either a tumor or plasma NGS test, or FISH
- FBXW7 deleterious mutations identified by either a tumor or plasma NGS test
- PPP2R1A deleterious mutations identified by either a tumor or plasma NGS test
- Measurable disease as per RECIST v1.1. For certain modules, patients with prostate cancer or ovarian cancer that have non-measurable disease but have elevated tumor markers (PSA or CA-125, respectively) can also be eligible
- Ability to swallow and retain oral medications.
- Acceptable hematologic and organ function at screening.
- Negative pregnancy test (serum) for women of childbearing potential (WOCBP) at Screening.
- Resolution of all toxicities of prior therapy or surgical procedures.
- Any prior radiation must have been completed at least 7 days prior to the start of study drugs, and patients must have recovered from any acute adverse effects prior to the start of study treatment.
Exclusion Criteria:
- Chemotherapy or small molecule antineoplastic agent given within 21 days or <5 half-lives, whichever is shorter, prior to first dose of study drug.
- History or current condition, therapy, or laboratory abnormality that might confound the study results or interfere with the patient's participation for the full duration of the study treatment.
- Patients who are pregnant or breastfeeding.
- Life-threatening illness, medical condition, active uncontrolled infection, or organ system dysfunction or other reasons which, in the investigator's opinion, could compromise the participating patient's safety.
- Major surgery within 4 weeks prior to first dose of lunresertib.
- Uncontrolled, symptomatic brain metastases.
- Uncontrolled hypertension.
- Certain prior anti-cancer therapy
- Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Phase 1: Lunresertib Single-Agent, Dose Escalation and Food-effect Study
Patients receive lunresertib orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified. |
Oral PKMYT1 Inhibitor |
|
Experimental: Phase 1: Lunresertib in combination with RP-3500, Dose Escalation Study
Patients receive lunresertib with RP-3500 orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified. |
Oral PKMYT1 Inhibitor Oral ATR Inhibitor |
|
Experimental: Phase 1: Lunresertib in combination with Zedoresertib, Dose Escalation Study
Patients receive lunresertib with zedoresertib orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified. |
Oral PKMYT1 Inhibitor Oral WEE1 Inhibitor
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Safety and Tolerability of lunresertib either in monotherapy or in combination with RP-3500 or with Zedoresertib in patients with eligible advanced solid tumors
Periodo de tiempo: Up to 90 days after last administration of study intervention
|
Assessed by treatment-emergent adverse events (TEAEs), physical examinations (PEs), safety laboratory assessments, electrocardiograms (ECGs), and vital sign measurements |
Up to 90 days after last administration of study intervention
|
|
To define the MTD of lunresertib monotherapy, and determine a recommended Phase 2 dose (RP2D) and preferred schedule
Periodo de tiempo: Up to 90 days after last administration of study intervention
|
Assessed by the incidence of Dose-limiting toxicities (DLTs) and the incidence and severity of cumulative safety data |
Up to 90 days after last administration of study intervention
|
|
To define the MTD of lunresertib in combination with RP-3500 or in combination with Zedoresertib, and determine a recommended Phase 2 dose (RP2D) and preferred schedule
Periodo de tiempo: Up to 90 days after last administration of study intervention
|
Assessed by the incidence of dose-limiting toxicities (DLTs) and the incidence and severity of cumulative safety data |
Up to 90 days after last administration of study intervention
|
|
The relative bioavailability of lunresertib capsule formulation as compared to lunresertib tablet formulation in the fasted state
Periodo de tiempo: Time 0 (time of dosing) to 72 hours post-dose for each treatment condition
|
Assessed by the plasma concentrations of lunresertib with calculation of pharmacokinetic (PK) parameters including maximum observed plasma concentration (Cmax), time to maximum observed plasma concentration (Tmax), area under the plasma concentration-time curve (AUC) , for both formulations in the fasted state. |
Time 0 (time of dosing) to 72 hours post-dose for each treatment condition
|
|
The effect of food on the PK of tablet formulation of lunresertib when administered in fed conditions compared to administration under fasted conditions
Periodo de tiempo: Time 0 (time of dosing) to 72 hours post-dose for each treatment condition
|
Assessed by the plasma concentrations of lunresertib with calculation of the ratio of PK parameters (e.g., Cmax and AUC) between the tablet formulation under fasted and fed state. |
Time 0 (time of dosing) to 72 hours post-dose for each treatment condition
|
|
To assess the safety and tolerability of lunresertib tablets in combination with RP-3500, confirm the MTD of lunresertib tablets in combination with RP-3500, and determine a RP2D and preferred schedule
Periodo de tiempo: Up to 90 days after last administration of study intervention
|
Assessed by DLTs, TEAEs, safety laboratory assessments, the incidence of DLTs and the incidence and severity of cumulative safety data |
Up to 90 days after last administration of study intervention
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The plasma concentrations of lunresertib monotherapy (capsule formulation) in the fasted and fed states
Periodo de tiempo: Up to 90 days after last administration of study intervention
|
Assessed by the plasma concentrations of lunresertib with calculation of maximum observed plasma concentration (Cmax), time to maximum observed plasma concentration (Tmax), minimum observed plasma concentration (Cmin), area under the plasma concentration-time curve (AUC), elimination half-life (t1/2), and other parameters as appropriate |
Up to 90 days after last administration of study intervention
|
|
To assess the relationship between pharmacodynamic biomarkers and PK of lunresertib at different dose levels and/or schedules
Periodo de tiempo: Up to 90 days after last administration of study intervention
|
Assessed by evaluation of biomarkers in pre- and on-treatment biopsies, and circulating tumor DNA (ctDNA) dynamics during treatment |
Up to 90 days after last administration of study intervention
|
|
The plasma concentrations of lunresertib and RP-3500 when dosed in combination
Periodo de tiempo: Up to 90 days after last administration of study intervention
|
Assessed by the plasma concentrations of lunresertib and RP-3500 with calculation of maximum observed plasma concentration (Cmax), time to maximum observed plasma concentration (Tmax), minimum observed plasma concentration (Cmin), area under the plasma concentration-time curve (AUC), elimination half-life (t1/2), and other parameters as appropriate for each analyte |
Up to 90 days after last administration of study intervention
|
|
To assess preliminary anti-tumor activity achieved with lunresertib monotherapy, lunresertib in combination with RP-3500 or lunresertib in combination with Zedoresertib
Periodo de tiempo: Through Study Completion, an average of 1 year
|
Measured by best percent change in tumor size from baseline, objective response rate (ORR), overall response rate, tumor marker response, duration of response (DOR), clinical benefit rate (CBR), progression-free survival (PFS). |
Through Study Completion, an average of 1 year
|
|
To assess the safety and anti-tumor effects of lunresertib capsule + RP-3500
Periodo de tiempo: Through Study Completion, an average of 1 year
|
As measure by TEAEs, safety laboratory assessments, Best percent change in tumor size from baseline, ORR, overall response rate, DOR, CBR, tumor marker response, PFS |
Through Study Completion, an average of 1 year
|
|
To further characterize the PK of lunresertib tablets and assess preliminary anti-tumor
Periodo de tiempo: Through Study Completion, an average of 1 year
|
Measured by Plasma concentrations of lunresertib with calculation of Cmax, Tmax, AUC, elimination t1/2, and other PK parameters as appropriate, Best percent change in tumor size from baseline, ORR, overall response rate, DOR, CBR, tumor marker response, PFS |
Through Study Completion, an average of 1 year
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
Otros números de identificación del estudio
- Debio 0123-106
- RP-6306-01 (Otro identificador: Repare Therapeutics)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .